GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just licensed to Novogen and start a Phase II trial for Glioma.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | mTOR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye